Abstrakt

Fluvastatin Combined with Benazepril May Contribute to Favorable Prognosis of Auricular Fibrillation

Hong Yao, Li Jiang, Xi Linand Zhao-Guang Liang

Objective: To observe the clinical significance of Fluvastatin combined with benazepril therapy on atrial fibrillation (AF). Methods: A total of 92 AF patients were randomly assigned into a case group (n=46) in which the patients were treated Fluvastatin plus benazepril and a control group (n=46) in which the patients were treated Fluvastatin. Results: Conversion rate of sinus was higher in the case group than the control group (P<0.05). The case group had more patients with significant efficacy than the control group, with less ineffective patients (P<0.05). The LVEDd, LVESd, LAD, and LVEF indexes in the case group were lower than the control group after 6 months of treatment (all P<0.05). The hs-CRP was decreased in the case group in comparison with the control group after 1 month of treatment (P<0.05). After 12 months, the renin and Ang II were lower in the case group than the control group (both P<0.05). Significant differences of IL-6 and TNF-α were found between the two groups after 1 month, 6 months, and 12 months of treatment (all P<0.05). Compared with the control group, the TC, triglyceride, LDL-C in the case group were lower after 6 and 12 months of treatment (all P<0.05), while the HDL was higher (P<0.05). Conclusions: Fluvastatin combined with benazepril treatment further increases conversion rate of sinus and remarkably improves life quality and prognosis of AF patients.